Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,389.49

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,841.22 5
Food and Beverage $548.27 30

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962543280?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $6,389.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $17.9112/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050229195 CMS
Lilly USA, LLC $22.9612/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031510001 CMS
Amgen Inc. $14.8812/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019972483 CMS
Abbott Laboratories $16.8111/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019586299 CMS
Amgen Inc. $16.4011/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020605673 CMS
AstraZeneca Pharmaceuticals LP $17.8811/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014659173 CMS
Otsuka America Pharmaceutical, Inc. $25.9610/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014764903 CMS
Amneal Pharmaceuticals LLC $12.7510/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053530405 CMS
AbbVie Inc. $26.2609/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724369 CMS
Novo Nordisk Inc $17.2509/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792141 CMS
Xeris Pharmaceuticals, Inc. $14.0708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056470115 CMS
Novartis Pharmaceuticals Corporation $22.8208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992730679 CMS
Novo Nordisk Inc $21.3008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792161 CMS
Amgen Inc. $14.4207/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020605671 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.5507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057489783 CMS
AbbVie Inc. $16.5807/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724365 CMS
AbbVie Inc. $19.6606/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724359 CMS
GlaxoSmithKline, LLC. $18.5505/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001355717 CMS
Novo Nordisk Inc $20.0005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792151 CMS
AbbVie Inc. $17.6704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724353 CMS
PFIZER INC. $14.9704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050283505 CMS
PFIZER INC. $400.0004/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050014413 CMS
AbbVie Inc. $21.7004/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998724347 CMS
Exact Sciences Corporation $15.7604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026641277 CMS
PFIZER INC. $3,000.0003/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049161737 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.4803/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996865223 CMS
PFIZER INC. $500.0003/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049160835 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.1203/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000324347 CMS
Abbott Laboratories $24.5403/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018771569 CMS
PFIZER INC. $10.3303/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049422011 CMS
Novo Nordisk Inc $16.0802/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792121 CMS
PFIZER INC. $1,541.2202/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049160829 CMS
PFIZER INC. $400.0002/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049161743 CMS
AstraZeneca Pharmaceuticals LP $13.3801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014166031 CMS
Novo Nordisk Inc $17.2301/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001792131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

193 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $591.50 12/31/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670123281
Principal investigator 1 Allergan Inc. $14,306.59 12/31/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670127509
Principal investigator 1 PFIZER INC. $4,950.46 12/24/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675911
Principal investigator 1 Allergan Inc. $780.00 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670117331
Principal investigator 1 Novo Nordisk AS $5,721.98 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453785
Principal investigator 1 Allergan Inc. $17,073.40 12/16/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670112395
Principal investigator 1 Kowa Research Institute, Inc. $1,521.00 12/16/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629130057
Principal investigator 1 Allergan Inc. $738.15 12/13/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670109721
Principal investigator 1 PFIZER INC. $12,221.49 12/05/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673531
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 12/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685013973
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 12/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685013989
Principal investigator 1 PFIZER INC. $1,256.84 12/04/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671670945
Principal investigator 1 Ferring International Pharmascience Center US $665.00 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228547
Principal investigator 1 Kowa Research Institute, Inc. $6,433.20 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629130059
Principal investigator 1 Novo Nordisk AS $6,727.72 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453783
Principal investigator 1 PFIZER INC. $628.42 11/23/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671673591
Principal investigator 1 PFIZER INC. $9,176.29 11/23/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678369
Principal investigator 1 Novo Nordisk AS $287.16 11/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704063
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 11/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough No dispute reported 06/30/2026 691501129
Principal investigator 1 PFIZER INC. $1,737.78 11/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675025
Principal investigator 1 Merck Sharp & Dohme Corporation $2,950.00 11/18/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691501747
Principal investigator 1 PFIZER INC. $17.56 11/18/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684557
Principal investigator 1 PFIZER INC. $145.50 11/18/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684627
Principal investigator 1 Allergan Inc. $738.15 11/14/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670097919
Principal investigator 1 Allergan Inc. $13,155.60 11/14/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670098213
Principal investigator 1 PFIZER INC. $628.42 11/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670045
Principal investigator 1 Novo Nordisk AS $50.00 11/12/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453773
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476653
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476967
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476971
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476973
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691476977
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691538873
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539521
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539523
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539691
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539693
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539695
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691541323
Principal investigator 1 PFIZER INC. $50.00 11/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669197
Principal investigator 1 PFIZER INC. $65.00 11/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673711
Principal investigator 1 PFIZER INC. $375.00 11/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675749
Principal investigator 1 PFIZER INC. $2.69 11/04/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684629
Principal investigator 1 PFIZER INC. $3,952.50 11/02/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671679079
Principal investigator 1 Allergan Inc. $666.24 10/31/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670093045
Principal investigator 1 PFIZER INC. $17.56 10/30/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684589
Principal investigator 1 PFIZER INC. $5.38 10/30/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684591
Principal investigator 1 PFIZER INC. $97.00 10/30/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684593
Principal investigator 1 Novo Nordisk AS $7,992.80 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453771
Principal investigator 1 Kowa Research Institute, Inc. $2,305.80 10/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629130055
Principal investigator 1 Allergan Inc. $10,411.05 10/23/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670090368
Principal investigator 1 PFIZER INC. $9,676.51 10/23/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669673
Principal investigator 1 PFIZER INC. $11,311.56 10/23/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671670943
Principal investigator 1 Allergan Inc. $872.10 10/17/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670086795
Principal investigator 1 Merck Sharp & Dohme Corporation $1,176.00 10/11/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691429933
Principal investigator 1 PFIZER INC. $4,001.38 10/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671668961
Principal investigator 1 PFIZER INC. $6,242.59 10/04/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672517
Principal investigator 1 PFIZER INC. $1,885.26 10/04/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671678029
Principal investigator 1 Ferring International Pharmascience Center US $1,031.70 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228261
Principal investigator 1 PFIZER INC. $1,372.27 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670291
Principal investigator 1 Kowa Research Institute, Inc. $8,316.90 10/01/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629130051
Principal investigator 1 Merck Sharp & Dohme Corporation $740.76 09/27/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691430915
Principal investigator 1 Merck Sharp & Dohme Corporation $741.95 09/27/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451471
Principal investigator 1 Novo Nordisk AS $7,625.86 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453781
Principal investigator 1 Allergan Inc. $9,805.90 09/20/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670078671
Principal investigator 1 Allergan Inc. $2,236.30 09/20/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670078967
Principal investigator 1 PFIZER INC. $12,289.55 09/20/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676179
Principal investigator 1 PFIZER INC. $3,603.82 09/11/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669239
Principal investigator 1 Merck Sharp & Dohme Corporation $1,475.00 09/09/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449653
Principal investigator 1 Novo Nordisk AS $6,861.24 09/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453779
Principal investigator 1 PFIZER INC. $2,356.59 08/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672927
Principal investigator 1 PFIZER INC. $13,068.70 08/28/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678325
Principal investigator 1 Ferring International Pharmascience Center US $6,680.40 08/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228035
Principal investigator 1 Ferring International Pharmascience Center US $3,406.70 08/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227953
Principal investigator 1 PFIZER INC. $1,942.99 08/20/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672515
Principal investigator 1 Allergan Inc. $9,861.00 08/16/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670066884
Principal investigator 1 PFIZER INC. $2,334.15 08/14/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678697
Principal investigator 1 Merck Sharp & Dohme Corporation $2,440.00 08/12/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449665
Principal investigator 1 Novo Nordisk AS $97.20 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703599
Principal investigator 1 PFIZER INC. $13,152.05 08/06/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678973
Principal investigator 1 Novo Nordisk AS $10,179.24 07/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453775
Principal investigator 1 Novo Nordisk AS $114.51 07/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453777
Principal investigator 1 PFIZER INC. $65.00 07/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671655573
Principal investigator 1 PFIZER INC. $50.00 07/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671655575
Principal investigator 1 PFIZER INC. $743.85 07/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671656849
Principal investigator 1 PFIZER INC. $375.00 07/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671657429
Principal investigator 1 Kowa Research Institute, Inc. $1,774.80 07/18/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629130009
Principal investigator 1 PFIZER INC. $3,712.83 07/18/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671671661
Principal investigator 1 PFIZER INC. $240.47 07/17/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671656653
Principal investigator 1 Merck Sharp & Dohme Corporation $1,797.00 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449655
Principal investigator 1 Merck Sharp & Dohme Corporation $3,000.00 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449667
Principal investigator 1 Merck Sharp & Dohme Corporation $9,174.00 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451475
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451583
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451589
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451593
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453555
Principal investigator 1 PFIZER INC. $17,219.37 07/10/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671671981
Principal investigator 1 PFIZER INC. $1,830.77 07/02/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671657911
Principal investigator 1 Allergan Inc. $7,000.00 07/01/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670054315
Principal investigator 1 Allergan Inc. $1,000.00 07/01/2019 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 670054317
Principal investigator 1 PFIZER INC. $1,372.27 06/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671657821
Principal investigator 1 Novo Nordisk AS $6,213.05 06/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453769
Principal investigator 1 PFIZER INC. $17,313.76 06/22/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671653803
Principal investigator 1 Novo Nordisk AS $200.40 06/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703535
Principal investigator 1 Allergan Inc. $1,040.00 06/18/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670051757
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389577
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390018
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390043
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390047
Principal investigator 1 PFIZER INC. $628.42 06/01/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671656503
Principal investigator 1 PFIZER INC. $1,885.26 05/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654775
Principal investigator 1 Novo Nordisk AS $9,325.20 05/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453767
Principal investigator 1 Kowa Research Institute, Inc. $2,889.90 05/22/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629129989
Principal investigator 1 PFIZER INC. $628.42 05/22/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654851
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14.69 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027899
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15.00 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027905
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $45.13 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027915
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $66.00 05/22/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027921
Principal investigator 1 Merck Sharp & Dohme Corporation $2,739.00 05/20/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691317005
Principal investigator 1 Novo Nordisk AS $80.04 05/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703427
Principal investigator 1 Novo Nordisk AS $80.04 05/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703429
Principal investigator 1 PFIZER INC. $2,069.55 05/18/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671658135
Principal investigator 1 PFIZER INC. $1,962.22 05/15/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654809
Principal investigator 1 PFIZER INC. $7,351.35 05/10/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654441
Principal investigator 1 Merck Sharp & Dohme Corporation $263.56 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389453
Principal investigator 1 Merck Sharp & Dohme Corporation $175.80 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389587
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389963
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390051
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396739
Principal investigator 1 PFIZER INC. $1,256.84 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654363
Principal investigator 1 PFIZER INC. $6,200.00 05/08/2019 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654777
Principal investigator 1 Allergan Inc. $1,004.00 05/07/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670043861
Principal investigator 1 Kowa Research Institute, Inc. $7,822.80 05/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629129991
Principal investigator 1 PFIZER INC. $375.00 05/01/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654419
Principal investigator 1 PFIZER INC. $3,821.87 05/01/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654811
Principal investigator 1 PFIZER INC. $65.00 05/01/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654813
Principal investigator 1 PFIZER INC. $506.25 05/01/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654853
Principal investigator 1 PFIZER INC. $100.00 05/01/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654855
Principal investigator 1 Novo Nordisk AS $10,223.32 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453763
Principal investigator 1 Novo Nordisk AS $187.50 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453765
Principal investigator 1 PFIZER INC. $10,683.14 04/23/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654439
Principal investigator 1 Merck Sharp & Dohme Corporation $3,872.00 04/12/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691318281
Principal investigator 1 PFIZER INC. $9,695.74 04/10/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654361
Principal investigator 1 PFIZER INC. $1,256.84 04/09/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654437
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389443
Principal investigator 1 Merck Sharp & Dohme Corporation $242.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389447
Principal investigator 1 Merck Sharp & Dohme Corporation $3.90 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389457
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389581
Principal investigator 1 Merck Sharp & Dohme Corporation $35.20 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389833
Principal investigator 1 Merck Sharp & Dohme Corporation $82.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389903
Principal investigator 1 Merck Sharp & Dohme Corporation $10.65 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390021
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390025
Principal investigator 1 Merck Sharp & Dohme Corporation $2.10 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390029
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390053
Principal investigator 1 Merck Sharp & Dohme Corporation $792.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390057
Principal investigator 1 Merck Sharp & Dohme Corporation $100.80 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390089
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390093
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391835
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391837
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391841
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396313
Principal investigator 1 Merck Sharp & Dohme Corporation $2.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396345
Principal investigator 1 PFIZER INC. $4,415.03 03/27/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654359
Principal investigator 1 Novo Nordisk AS $18,627.88 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453761
Principal investigator 1 PFIZER INC. $6,347.37 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654381
Principal investigator 1 PFIZER INC. $8,769.13 03/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654773
Principal investigator 1 Merck Sharp & Dohme Corporation $2,172.00 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691317789
Principal investigator 1 PFIZER INC. $1,256.84 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654871
Principal investigator 1 PFIZER INC. $2,849.55 03/05/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654379
Principal investigator 1 Merck Sharp & Dohme Corporation $2,964.00 03/04/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691326441
Principal investigator 1 Novo Nordisk AS $20,486.39 02/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453759
Principal investigator 1 Amarin Pharma Inc. $5,285.50 02/21/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio No dispute reported 06/30/2026 700952273
Principal investigator 1 PFIZER INC. $1,256.84 02/20/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654383
Principal investigator 1 PFIZER INC. $3,472.37 02/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671655047
Principal investigator 1 PFIZER INC. $5,162.07 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654801
Principal investigator 1 Kowa Research Institute, Inc. $693.00 02/07/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629129967
Principal investigator 1 Novo Nordisk AS $160.68 02/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703287
Principal investigator 1 PFIZER INC. $5,310.37 02/05/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671657933
Principal investigator 1 PFIZER INC. $3,459.53 02/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671655143
Principal investigator 1 Merck Sharp & Dohme Corporation $1,053.17 01/28/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396278
Principal investigator 1 Merck Sharp & Dohme Corporation $1,264.00 01/25/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691308773
Principal investigator 1 Novo Nordisk AS $275.00 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453755
Principal investigator 1 Novo Nordisk AS $28,628.82 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692453757
Principal investigator 1 PFIZER INC. $15,082.08 01/23/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671654841
Principal investigator 1 Kowa Research Institute, Inc. $1,386.00 01/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 629129969
Principal investigator 1 PFIZER INC. $13,741.99 01/16/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654991
Principal investigator 1 PFIZER INC. $13,652.48 01/16/2019 Non-covered Recipient Entity
PMG Research of Raleigh
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671658155
Principal investigator 1 PFIZER INC. $65.00 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671654761
Principal investigator 1 PFIZER INC. $375.00 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671655145
Principal investigator 1 PFIZER INC. $2,900.00 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671655183
Principal investigator 1 PFIZER INC. $100.00 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671658101
Principal investigator 1 Merck Sharp & Dohme Corporation $5,136.00 01/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691310701
Principal investigator 1 Merck Sharp & Dohme Corporation $2,917.29 01/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691311007